top of page

Morphocell Technologies welcomes Patrick Bedford as Vice President of Regulatory Affairs

PBedford Headshot.jpg

Montreal, QC, April 22, 2024 – Morphocell Technologies is thrilled to announce the appointment of Patrick Bedford as our new Vice President of Regulatory Affairs.


Patrick joins us with an impressive background, bringing over 18 years of experience in cell and gene therapy clinical translation. His expertise will be instrumental as we continue to innovate and lead in the cell therapy industry. Patrick holds a Health Sciences degree from the University of Western Ontario, complemented by a Master’s of Bioethics and Health Law from Otago University, and an MBA from the Jack Welch Management Institute. His comprehensive education has provided him with a unique blend of knowledge that spans across health science, ethics, law, and business management, making him exceptionally well-equipped to lead our regulatory initiatives.

Before joining Morphocell, Patrick led Health Canada’s regulatory initiatives for biosimilars, transplant materials, and cell & gene therapies. His leadership in these areas has been crucial in shaping regulatory frameworks that support innovation while ensuring safety and compliance.

In North America, Patrick has been an active player in policy development, and supported dozens of cell & gene therapy companies at various stages of development—from preclinical through to commercial phases. His efforts have helped many organizations navigate the complex regulatory landscape efficiently, reducing time to market for vital therapies.

Beyond his regulatory prowess, Patrick is a passionate educator and mentor. He has lectured at multiple universities and supported early-stage companies, enriching the cell & gene therapy ecosystem. His commitment to fostering growth and innovation in this field is evident through his regular contributions to workshops and conferences across Canada.

Max Paganelli, CEO of Morphocell Technologies, expressed his enthusiasm about Patrick's appointment, saying, "Patrick's deep understanding of the regulatory process and his proactive approach to leadership are exactly what we need as we aim to set new standards in cell therapy development. His arrival marks a significant step forward for our team’s capabilities."

Upon joining the team, Patrick Bedford shared, "I am excited to join Morphocell Technologies at this pivotal time. The opportunity to lead regulatory strategies for such innovative therapies is not only a professional honor but also a personal commitment to advancing healthcare. I look forward to working with the team to bring transformative treatments to those who need them most."

As Vice President, Regulatory Affairs, Patrick will lead Morphocell Technologies’ strategies for navigating the regulatory environment throughout the development process. His appointment is a testament to our commitment to meeting the highest standards of compliance and efficacy in the treatments we develop.

Please join us in welcoming Patrick Bedford to the Morphocell family. We look forward to his leadership in pushing the boundaries of what is possible in cell & gene therapy, ensuring that we continue to deliver breakthrough solutions that improve patient lives worldwide.


About Morphocell Technologies:

Morphocell Technologies Inc. is a Montreal-based regenerative medicine company focused on the development and commercialization of stem cell-derived tissue and organ replacement therapies. Its iPSC-derived platform technology has a large pipeline potential touching different organ deficiencies, with severe liver disease being the initial focus. Morphocell prides itself on its culture of innovation, technical excellence, and commitment to improving patients' lives. 


Media Contact:

Zaynah Ibrahim

+ 1 (514) 373-6444 ext. 106

bottom of page